A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
2009

MVTT Vaccine Induces Higher Antibody Levels than MVA

Sample size: 18 publication 10 minutes Evidence: high

Author Information

Author(s): Huang Xiaoxing, Lu Bin, Yu Wenbo, Fang Qing, Liu Li, Zhuang Ke, Shen Tingting, Wang Haibo, Tian Po, Zhang Linqi, Chen Zhiwei

Primary Institution: Wuhan University, Hubei, People's Republic of China

Hypothesis

Does the novel MVTT vaccine induce higher levels of neutralizing antibodies compared to the MVA vaccine when administered via mucosal routes?

Conclusion

The MVTT vaccine is superior to MVA for inducing high levels of neutralizing antibodies through mucosal vaccination.

Supporting Evidence

  • MVTT-S induced 20-to-100-fold higher levels of neutralizing antibodies than MVA-S via mucosal routes.
  • Pre-existing immunity to wild-type VTT impaired the antibody response to MVTT-S.
  • MVTT is an attractive live viral vector for mucosal vaccination.

Takeaway

The MVTT vaccine works better than the MVA vaccine at making the body fight off viruses when given through the nose or mouth.

Methodology

The study compared the immune responses of mice vaccinated with MVTT and MVA using various routes of administration.

Potential Biases

Potential bias in the selection of vaccine doses and routes of administration.

Limitations

The study was conducted in mice, which may not fully represent human responses.

Participant Demographics

Mice used in the study were six-week-old female BALB/c mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0004180

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication